Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis’ appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
The High Court won’t hear Bayer’s appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company’s claim the decision has “profound” consequences for drug R&D.
Australian cancer care company GenesisCare has been sued by Novartis unit Endocyte for allegedly infringing the patents for its prostate cancer treatment Pluvicto. The lawsuit, filed in the Federal Court in January, accuses GenesisCare of infringing or threatening to infringe patents held by Endocyte and Purdue Research Foundation by supplying lutetium, the generic version of…
A finding that Noumi’s production of a PwC report to ASIC didn’t constitute waiver of privilege provides clarity that voluntary disclosure agreements can protect confidential information, but care must still be taken, lawyers say.
The High Court has rejected Aristocrat’s request that it rule again on the patentability of its popular Lightning Link game, after a differently comprised court was split on when computer-implemented inventions can be patented.
An appeals court has overturned a finding that food company Noumi waived privilege over a PwC report commissioned by Ashurst, which it produced to ASIC under voluntary disclosure.
Fast food giant McDonald’s has resolved its dispute over misleading burger ads by Hungry Jack’s, ending a heated four-year courtroom battle.
The Full Court has overturned a finding that singer Katy Perry infringed an Australian fashion designer’s ‘Katie Perry’ mark, finding the designer knew of the pop star when she registered the mark.
ASIC wants the Full Court to overturn a finding that Noumi waived privilege over a PwC report produced under a voluntary disclosure regime, arguing the regime benefits the public in making investigations more efficient.
The Commonwealth has lost its bid to pause a long-running dispute over a generic form of brand drug Abilify while the High Court hears a different generic drug battle.